Loading...

URGN UROGEN PHARMA LTD Legal Disputes 8-K Filing

RGN

RGN

UROGEN PHARMA LTD

(URGN)

2026 8-K

Patent Settlement

Financial Results Announcement

Financial Results Report

Loan Agreement Details

Financial Results Report

Shareholder Approvals

Financial Statements

Compensatory Arrangements o...

New Product Launches

Financial Statements

Financial Results

Asset Acquisition

Investor Presentation

Financial Results

Director Resignation

Financial Results

Annual Meeting Approval

Public Offering

Positive Data from Phase 3 ...

Financial Results Announcement

Financial Results Announcement

Presentation at Conference

Notice of ANDA Submission

Agreement and Phase 3 Study

Amendment to Manufacturing ...

Financial Results Announcement

Annual Meeting of Shareholders

Financial Results Announcement

Private Placement

Financial Results Announcement

External Links:

On June 2, 2026, UroGen Pharma Ltd. entered into a settlement with Teva Pharmaceuticals regarding the patent litigation over Jelmyto, allowing Teva to sell a generic version starting September 15, 2030, pending FDA approval. The agreement resolves ongoing lawsuits between the companies and is subject to review by regulatory authorities.

AI Assistant

UROGEN PHARMA LTD

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.